News

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...
2 Beaten-Down Stocks With Incredible Upside Potential
Iovance Biotherapeutics ( IOVA -1.52%) and CRISPR Therapeutics ( CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have ...
National Academy of Sciences15h
National Academy of Sciences Elects Members and International Members
The National Academy of Sciences announced today the election of 120 members and 30 international members in recognition of ...
Zacks Investment Research on MSN20h
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
The market expects Entrada Therapeutics, Inc. (TRDA) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known ...
Investing Snacks9h
Trikafta Triumph? Vertex Tees Up Q1 Blowout
Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report), Vertex Pharmaceuticals (VRTX – Research Report ...